IRWD - Ironwood and Allergan report positive topline data for Linzess Phase IIIb June, 18 2019 04:29 PM Ironwood Pharmaceuticals Inc. Ironwood Pharmaceuticals (NASDAQ:IRWD) and Allergan (NYSE:AGN) report that Linzess (linaclotide) 290 mcg met its primary multi-component endpoint in a Phase IIIb study.More news on: Ironwood Pharmaceuticals, Inc., Allergan plc, Healthcare stocks news, Stocks on the move, Read more ...